$DIVISLAB: More Than a Generic API Player

Divi’s Labs $DIVISLAB is steadily transforming into a high-value global CDMO partner, supported by the ramp-up of its Kakinada facility, expansion in peptide manufacturing, and growing Custom Synthesis business. Custom Synthesis now contributes over half of total revenue, strengthening the company’s long-term growth and profitability profile. Despite trading at a premium valuation, the market is factoring in future earnings growth from large-scale capacity expansion, contrast media opportunities, and peptide commercialization. With industry-leading margins and a debt-free balance sheet, Divi’s remains well-positioned for the next phase of growth.